Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov:31 Suppl 26:11-13.
doi: 10.1111/pai.13351.

The evolution of allergen-specific immunotherapy: The near and far future

Giovanni Battista Pajno  1 , Stefano Passanisi  1 , Mariella Valenzise  1 , Maria Francesca Messina  1 , Fortunato Lombardo  1
Affiliations

The evolution of allergen-specific immunotherapy: The near and far future

Giovanni Battista Pajno et al. Pediatr Allergy Immunol. 2020 Nov.

Abstract

In the era of precision medicine, allergen immunotherapy (AIT) represents a landmark for the management of IgE-mediated allergic diseases. AIT is recognized as a potentially curative therapy and is currently accepted and routinely prescribed worldwide. However, there are still unmet needs. The efforts of researchers are aimed at implementing current immunotherapeutic strategies to improve the standard care of patients suffering from IgE-mediated respiratory allergic diseases. In addition, over the horizon, the most realistic option is the active treatment of IgE-mediated food allergy with oral immunotherapy. Preclinical studies and clinical trials are increasingly conducted to identify innovative forms of AIT administration, potential biomarkers, alternative immunotherapeutic allergen candidates, and new adjuvants. Telemedicine could represent a further emerging field capable of supporting health service delivery and improving clinical outcomes of AIT.

Keywords: adjuvants; biologics; mobile health; oral immunotherapy; precision medicine; wild-type allergens.

PubMed Disclaimer

References

REFERENCES

    1. Dorofeeva Y, Shilovskly I, Tulaeva I, et al. Past, presence, and future of allergen immunotherapy vaccines. Allergy. 2020. https://doi.org/10.1111/all.14300. [Online ahead of print]
    1. Pajno GB, Fernandez-Rivas M, Arasi S, et al. EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy. 2018;73:799-815.
    1. Dantzer JA, Wood RA. The use of omalizumab in allergen immunotherapy. Clin Exp Allergy. 2018;48:232-240.
    1. Pechsrichuang P, Jacquet A. Molecular approaches to allergen-specific immunotherapy: Are we so far from clinical implementation? Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2020;50:543-557.
    1. Zhernov Y, Curin M, Khaitov M, et al. Recombinant allergens for immunotherapy: state of the art. Curr Opin Allergy Clin Immunol. 2019;19:402-414.

LinkOut - more resources